Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

MaxiNovel Pharmaceuticals

Request full access

A China based biotech company focused on the innovative drug research with the global intellectual property rights

ChinaBiotech & Life Sciences

About MaxiNovel Pharmaceuticals

MaxiNovel, founded in 2016, is a China-based biotech company specializing in innovative drug research with global intellectual property rights. The company focuses on first-in-class small molecule drug discovery, particularly in targeted therapy and immunotherapy. MaxiNovel's rapidly expanding product pipeline includes programs aimed at treating blood tumors, solid tumors, and autoimmune diseases. The company's research platforms encompass oral therapy, radiotherapy, imaging, and transdermal therapy. MaxiNovel operates R&D and operation centers in Shanghai, Guangzhou, Shenzhen, the United States, and Australia. One of its notable products, MAX 40070, is a topical JAK Tyk2 inhibitor currently in Phase I/II clinical trials for solid tumors and autoimmune skin diseases such as alopecia areata, atopic dermatitis, and psoriasis. The company aims to address safety concerns associated with long-term systemic drug exposure by developing topical treatments. MaxiNovel generates revenue through the development and commercialization of its proprietary drugs, targeting both domestic and international markets. The company serves a diverse clientele, including hospitals, research institutions, and pharmaceutical companies.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
24.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC Oct 2022 $14M $56M Lapam Capital · Deyi Capital · Zhongxin Capital Holdings ↗
SERIES C✓Equity / VC Jan 2021 $28M $110M Youchoose Capital · Dyee Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

MaxiNovel Pharmaceuticals website traffic

Latest recorded traffic for MaxiNovel Pharmaceuticals is 920 monthly website visits, up 43.8% over the last three months.

Latest monthly visits920 3-month web change+43.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

MaxiNovel Pharmaceuticals in its local ecosystem

Live from Dealroom

The MaxiNovel Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later5 investors entered at this stage

  • Youchoose Capital
  • Dyee Capital
  • Lapam Capital
  • Deyi Capital
  • Zhongxin Capital Holdings
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about MaxiNovel Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MaxiNovel Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.